Search the Newsreel

HC Wainwright Boosts Earnings Estimates for Delcath Systems

HC Wainwright has increased its Q3 2026 EPS estimate for Delcath Systems (NASDAQ: DCTH) from a loss of $0.29 to a loss of $0.10, maintaining a "Buy" rating and a $32 price target. This revision follows Delcath's strong Q2 earnings report, where the company …

Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?

Shares of Delcath Systems, Inc. (DCTH) have recently gained 29.5%, and Wall Street analysts project a further potential upside of 42.8%, with a mean target price of $23.8. While analysts' price targets can be overly optimistic, the agreement among analysts on higher earnings estimates …

Statutory Earnings May Not Be The Best Way To Understand Mediwelcome Healthcare Management & Technology's (HKG:2159) True Position

Delcath Systems resumes post-earnings momentum with 10% rally, sets new high (DCTH:NASDAQ)

Understanding the Setup: (CELC) and Scalable Risk

An analysis of Celcuity Inc. (NASDAQ: CELC) indicates strong near-term sentiment but elevated downside risk. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The article highlights the importance of institutional trading strategies for optimizing …

FuelCell Energy (NASDAQ:FCEL) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen has downgraded FuelCell Energy (NASDAQ:FCEL) from a "hold" to a "sell" rating, reflecting mixed analyst opinions though the broader consensus remains "hold" with an average price target of $22.83. This downgrade follows FuelCell Energy missing analyst expectations for both quarterly earnings …

Noticias de acciones de Fuelcell Energy Inc (FCEL)

Celcuity Inc (CELC) Stock News Today

This page provides current news and analysis for Celcuity Inc (CELC), including its stock performance and market data. It lists recent stock movements for other pharmaceutical companies like Bristol-Myers Squibb Co (BMY), Novo Nordisk A/S (NVO), and Merck & Co Inc (MRK). The content …

Delcath Systems (DCTH) Stock Profit Turn Faces Pricing Pressure

Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Delcath Systems (NASDAQ:DCTH) from a "hold" to a "buy" rating, with other analysts maintaining buy ratings and raising price targets, leading to a consensus "Moderate Buy" rating and an average price target of $23.17. The company recently reported strong quarterly …

Melco Resorts & Entertainment Limited เตรียมประกาศผลประกอบการทางการเงินประจำไตรมาสที่ 2 ปี 2026 ในวันที่ 13 สิงหาคม

Melco Resorts & Entertainment Limited (MLCO) มีกำหนดประกาศผลประกอบการทางการเงินประจำไตรมาสที่ 2 ปี 2026 ในวันพฤหัสบดีที่ 13 สิงหาคม 2026 ก่อนตลาดหลักทรัพย์สหรัฐอเมริกาจะเปิดทำการ บริษัทจะจัดการประชุมทางโทรศัพท์และเว็บคาสต์สดในวันเดียวกันเพื่อหารือเกี่ยวกับผลประกอบการ

Delcath Systems (NASDAQ:DCTH) Issues Earnings Results, Beats Estimates By $0.16 EPS

Delcath Systems (NASDAQ:DCTH) reported stronger-than-expected Q2 earnings, with EPS of $0.07 against an estimated loss of $0.09, and revenue reaching $29.13 million, surpassing expectations. The company raised its full-year 2026 revenue guidance to $104 million-$108 million, driven by a 21% year-over-year increase in HEPZATO …

Delcath Systems Inc (DCTH) Stock News Today

Melco Resorts & Entertainment L (MLCO) Stock forecasts

Melco Resorts & Entertainment Limited (MLCO) is a licensed casino operator in Macao, operating Altira, City of Dreams, and Mocha Clubs. A recent report by Morningstar highlights Melco Resorts' new project initiatives, which are expected to strengthen its competitiveness in the premium mass market. …

Celcuity faces investigation after FDA approval delays cause stock to drop 17.6%.

Pomerantz LLP is investigating Celcuity Inc. for potential securities fraud. This follows a 17.6% stock drop on July 15, 2026, after Celcuity announced delays in the commercial launch of its FDA-approved breast cancer therapy, Revtorpyk. The investigation aims to determine if unlawful business practices …

Delcath Systems, Inc. Stock 12‑Month Price Target Raised to $24.17, Implies 91% Upside

Delcath Systems, Inc. (DCTH) has seen its average 12-month price target raised to $24.17 by 6 analysts, up from $22.5, with individual forecasts ranging from $21 to $30. This updated target suggests a potential upside of approximately 91% from its August 5th closing price. …

Melco Resorts & Entertainment (Nasdaq: MLCO) plans Q2 2026 results call

Melco Resorts & Entertainment Limited (Nasdaq: MLCO) announced it will release its unaudited financial results for the second quarter of 2026 on Thursday, August 13, 2026. A conference call will be held on the same day at 8:30 a.m. Eastern Time. The company operates …

Melco Announces Earnings Release Date

Melco Resorts & Entertainment Limited (Nasdaq: MLCO) announced it will release its unaudited financial results for the second quarter of 2026 on Thursday, August 13, 2026. A conference call will follow on the same day at 8:30 a.m. Eastern Time, with registration details and …

FuelCell Energy prices $225 million stock offering at $21 By Investing.com

FuelCell Energy Inc. (NASDAQ:FCEL) has priced an underwritten public offering of 10,714,286 shares of common stock at $21.00 per share, aiming to raise $225 million. This offering, an increase from a previously announced $200 million, will fund capital expenditures, working capital, and general corporate …

Bloom Energy Is Down 20% in a Month. Is It Time to Switch to Plug Power or FuelCell Energy?

Bloom Energy's stock has dropped 20% in the last month, despite being the only profitable company among its peers, trading at a high 303x trailing P/E. While Plug Power and FuelCell Energy appear cheaper, they are unprofitable and carry higher risk. Investors seeking diversified …

Earnings call transcript: Delcath jumps on Q2 2026 revenue beat and raised outlook

Delcath Systems reported strong Q2 2026 results, exceeding revenue forecasts with $29.1 million, driven by demand for its HEPZATO KIT for metastatic uveal melanoma. The company raised its full-year 2026 revenue guidance to $104 million-$108 million and saw its shares jump in premarket trading. …

Celcuity Inc. (CELC) Stock Price, News, Quote & History

This page provides a comprehensive overview of Celcuity Inc. (CELC) stock, including its real-time price, historical data, and financial performance. It highlights the company's focus on developing targeted therapies for solid tumors and its lead drug candidate, Gedatolisib. The page also includes analyst insights, …

FuelCell Energy Inc. stock falls Thursday, underperforms market

FuelCell Energy Inc. (FCEL) stock fell by 3.88% on Thursday, closing at $20.32. This performance underperformed the broader market, as the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for FuelCell Energy shares.

Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research

BTIG Research has raised its price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from $17.00, maintaining a "Buy" rating and implying a 40% upside. This follows Delcath's strong quarterly performance, where it exceeded revenue and EPS expectations. The stock surged 18.8% to $15.00 on …

Delcath Systems Inc (DCTH) Beats Revenue Estimates with $29.1 Million in Q2 Earnings: GF Score 73/100, 66.7% Undervalued

Delcath Systems Inc (DCTH) reported Q2 2026 revenue of $29.1 million, surpassing analyst estimates, driven by strong HEPZATO KIT sales. Despite increased R&D expenses, the oncology company maintained stable net income and improved gross margins. Delcath is well-positioned for future growth with a robust …

Delcath Systems Q2 Earnings Call Highlights

Delcath Systems reported strong Q2 2026 results with a 20% year-over-year revenue increase to $29.1 million, driven by a 30% rise in HEPZATO KIT volume. The company raised its full-year 2026 revenue guidance to $104 million–$108 million and expects positive adjusted EBITDA. Delcath is …

Renaissance Technologies LLC Sells 333,000 Shares of FuelCell Energy, Inc. $FCEL

Renaissance Technologies LLC reduced its stake in FuelCell Energy, Inc. (NASDAQ:FCEL) by 27.3%, selling 333,000 shares in the first quarter but still holding 886,600 shares valued at approximately $5.8 million. Despite some analyst upgrades and raised price targets, the company reported a quarterly loss …

Delcath Systems (NASDAQ:DCTH) Sets New 12-Month High After Better-Than-Expected Earnings

DELCATH SYSTEMS, INC. 1Q 2026: Revenue $29.13M, EPS $0.07— 10-Q Summary

DELCATH SYSTEMS, INC. reported its first-quarter 2026 results, showing revenue of $29.13 million, a 20.6% increase year-over-year, and diluted EPS of $0.07, which was flat compared to the prior year. Net income was $2.67 million, a slight decrease of 1.1%. The revenue growth was …

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity Inc. announced it will release its second quarter 2026 financial results after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference on the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate …

Delcath's global Phase 2 trial doses first patient in breast cancer

Delcath Systems announced strong second-quarter 2026 financial results, reporting total revenue of $29.1 million and raising its full-year 2026 revenue guidance to between $104 million and $108 million. The company also highlighted the dosing of the first patient in its global Phase 2 trial …

Delcath Systems (NASDAQ: DCTH) posts Q2 profit and builds oncology pipeline

Delcath Systems reported a profitable Q2 2026 with $29.1 million in revenue, driven by increased adoption of its liver cancer therapies, HEPZATO KIT and CHEMOSAT. The company achieved a net income of $2.7 million and is advancing Phase 2 clinical trials for HEPZATO in …

Delcath Systems Q2 2026: Revenue $29.1M, Gross Margin 90%, Raises 2026 Guidance to $104M–$108M

Delcath Systems reported strong Q2 2026 results, with product revenue reaching $29.1 million and gross margin at 90%. The company achieved a net income of $2.7 million and adjusted EBITDA of $7.6 million, largely driven by HEPZATO KIT sales. Consequently, Delcath Systems has raised …

Delcath Q2 2026 Earnings: Revenue Rises While Clinical Spending Pressures EBITDA

Delcath Systems reported a 21% increase in Q2 2026 revenue, reaching $29.1 million, driven primarily by HEPZATO KIT sales. Despite a 90% gross margin and lower cost of goods sold, higher clinical and commercial spending led to a decline in non-GAAP adjusted EBITDA and …

Celcuity (CELC) Expected to Announce Earnings on Thursday

Delcath Systems Inc (DCTH) Earnings Date & Reports & Earnings News